selected scholarly activity
-
conferences
- PRIOR THERAPY WITH SOFOSBUVIR/VELPATASVIR ASSOCIATED WITH REDUCED RESPONSE TO SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR: RESULTS FROM A CANADIAN PROSPECTIVE REGISTRY. Hepatology. 981A-981A. 2019
- Sofosbuvir-velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. Journal of Gastroenterology and Hepatology. 102-102. 2019
- IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis. Gut. A138.1-A138. 2019
- Characteristics and sustained virologic response of persons reporting illicit substance use in the past 6 months: Results from the CANUHC prospective patient registry. Journal of Hepatology. E508-E508. 2019
- GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. Journal of Hepatology. e2-e3. 2019
- THU-179-Never too old to be direct acting antiviral treated for hepatitis C virus. Journal of Hepatology. e240-e241. 2019
- THU-393-HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort. Journal of Hepatology. e328-e328. 2019
- Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing Dialysis. Hepatology. 1456A-1456A. 2018
- Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World. Hepatology. 360A-361A. 2018
- Efficacy and safety of Sofosbuvir/Velpatasvir for the treatment of treatment-naive, non-cirrhotic patients with chronic hepatitis C genotype 3 infection: integrated analysis of three phase 3 clinical trials. Journal of Viral Hepatitis. 196-197. 2018
- Z-PROFILE: real-world utilization and effectiveness of Elbasvir/Grazoprevir in adult patients with chronic hepatitis C in Canada - final study results. Journal of Viral Hepatitis. 68-68. 2018
- Z-PROFILE: Real-world utilization and effectiveness of elbasvir/ grazoprevir in adult patients with chronic hepatitis C in Canada. Journal of Hepatology. S295-S296. 2018
- Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir Based Regimens. Hepatology. 121A-121A. 2017
- Real-world utilization of the new fixed-dose combination elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study. Journal of Hepatology. S307-S308. 2017
- A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study. Hepatology. 135A-136A. 2016
- Ledipasvir/Sofosbuvir with Ribavirin for 12 Weeks is Effective and Safe in Treatment-Naïve Genotype-3 Hepatitis C-Infected Patients in Canada. Journal of Hepatology. S781-S781. 2016
- Cloning of a Chromosomal Region Responsible for Streptolysin S Production in Streptococcus pyogenes. Advances in Experimental Medicine and Biology. 733-736. 1997
-
journal articles
-
Mixed‐Genotype
HCV Direct Acting Antiviral Outcomes: ACANUHC Analysis. Journal of Viral Hepatitis. 31:775-779. 2024 - Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.. Expert Review of Anti-Infective Therapy. ahead-of-print:1-8. 2024
- How is ceftobiprole used in Canada: the CLEAR study final results. Expert Review of Anti-Infective Therapy. 22:1-8. 2024
- Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders. Viruses. 14:2493-2493. 2022
- Remdésivir chez les patients hospitalisés pour la COVID-19 au Canada: essai clinique randomisé et contrôlé. CANADIAN MEDICAL ASSOCIATION JOURNAL. 194:E713-E723. 2022
- Combination of antibody tests against SARS-CoV-2 for health care workers after vaccination. Clinical Biochemistry. 101:54-55. 2022
- Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CANADIAN MEDICAL ASSOCIATION JOURNAL. 194:E242-E251. 2022
- Reply to: “Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy”. Journal of Hepatology. 75:1007-1008. 2021
- Standard versus combined chemical, mechanical, and heat decontamination of hospital drains harboring carbapenemase-producing organisms (CPOs): A randomized controlled trial. Infection Control and Hospital Epidemiology. 42:1275-1278. 2021
- Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis. Canadian Liver Journal. 4:283-291. 2021
- Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. Journal of Global Antimicrobial Resistance. 25:346-350. 2021
- Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. Clinical Infectious Diseases. 72:e799-e805. 2021
- Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. The Lancet Respiratory Medicine. 9:498-510. 2021
- Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry. Journal of Global Antimicrobial Resistance. 24:335-339. 2021
- Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older. JGH Open. 5:253-257. 2021
- Carbapenemase-producing Enterobacterales in hospital drains in Southern Ontario, Canada. Journal of Hospital Infection. 106:820-827. 2020
- Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health. 20:1345. 2020
- Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver International. 40:1841-1852. 2020
- The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C. Canadian Liver Journal. 3:251-262. 2020
- Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. Journal of Hepatology. 71:660-665. 2019
- Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis. 26:1127-1138. 2019
- Infection prevention and control practices related to carbapenemase-producing Enterobacteriaceae (CPE) in acute-care hospitals in Ontario, Canada. Infection Control and Hospital Epidemiology. 40:1006-1012. 2019
- Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial. Canadian Liver Journal. 2:91-107. 2019
- Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification. Open Forum Infectious Diseases. 6:ofz076. 2019
- Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. Journal of Infectious Diseases. 218:1722-1729. 2018
- Emergence of Carbapenemase-ProducingEnterobacteriaceae, South-Central Ontario, Canada1. Emerging Infectious Diseases. 24:1674-1682. 2018
- Real-life management of chronic hepatitis C virus infection in Canada: Description of patient profile, prognostic factors and treatment strategies. Journal of the Canadian Association of Gastroenterology. 1:326-328. 2018
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 153:113-122. 2017
- Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clinical Infectious Diseases. 65:13-19. 2017
- FibroScan® access in Canada: Time for reform, a call for universal access.. Canadian Journal of Gastroenterology and Hepatology. 29:221-222. 2015
- Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Canadian Journal of Gastroenterology. 29:220-221. 2015
- Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada. Canadian Journal of Gastroenterology and Hepatology. 29:125-129. 2015
- Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada. Clinical Infectious Diseases. 55:e109-e117. 2012
- Brucellosis in a returned traveller. CANADIAN MEDICAL ASSOCIATION JOURNAL. 183:E690-E692. 2011
- Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Medical Mycology. 44:659-664. 2006
- Group A Streptococcal Sepsis Secondary to Peritonitis and Acute Pelvic Inflammatory Disease. European Journal of Clinical Microbiology and Infectious Diseases. 20:0437-0439. 2001
- Reduced Virulence of Group A Streptococcal Tn 916 Mutants That Do Not Produce Streptolysin S. Infection and Immunity. 66:1671-1679. 1998
- Acidic pH changes receptor binding specificity of Helicobacter pylori: a binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization. Infection and Immunity. 64:2643-2648. 1996
-
Mixed‐Genotype